Some benefits include mitigation of cardiac toxicity, peripheral neuropathy, cognitive impairment, and dyspnea
THURSDAY, May 1, 2025 (HealthDay News) — Exercise mitigates adverse outcomes associated with cancer and its treatments, according to a review published online April 29 in the British Journal of Sports Medicine.
Xue-Li Bai, from the Fourth Affiliated Hospital of China Medical University in Shenyang, and colleagues conducted a systematic literature review to examine the comprehensive health impacts of exercise on people with cancer.
Based on 80 articles, all rated as moderate-to-high quality, the researchers found that 260 of the 485 associations (53.6 percent) were statistically significant and 81 (16.7 percent) were supported by high-certainty evidence according to the Grading of Recommendations Assessment, Development, and Evaluation criteria. There was moderate- to high-certainty evidence that exercise significantly mitigates adverse events associated with cancer and its treatments (e.g., cardiac toxicity, chemotherapy-induced peripheral neuropathy, cognitive impairment, and dyspnea), compared with usual care or no exercise. In people with cancer, exercise also modulated body composition and biomarkers (e.g., insulin, insulin-like growth factor-1, insulin-like growth factor-binding protein-1, and C-reactive protein) and enhances sleep quality, psychological well-being, physiological functioning, social interaction, and overall quality of life.
“Exercise reduces adverse events and enhances well-being through a range of health outcomes in people with cancer,” the authors write. “This study reinforces the efficacy of incorporating exercise into cancer treatment protocols.”
Structured Exercise Should Be Considered as Adjunct Therapy for Cancer
Strength Training Not Tied to Ventricular Arrhythmia in Those With Arrhythmogenic Cardiomyopathy
AACR Annual Report Highlights Progress in Cancer Research
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus
Therapies Compared for Newly Diagnosed Multiple Sclerosis
Initial Rx Length Tied to Long-Term Use of Z-Drugs